HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Action Items For CBD Policy? The List Is Short Due To 'Critical' Data Gaps

Executive Summary

FDA has little in the way of good information it can list on its CBD policy agenda so far, says Principal Deputy Commissioner Amy Abernethy. At recent regulatory conference, she said, "Like it or not, there is a massive human experiment going on right now. There’s CBD in most different product categories and people of many different backgrounds with potential vulnerabilities taking CBD."

You may also be interested in...



New Report, Same Theme On US FDA's Policy On Cannabidiols: ‘Extensive Data Gaps’ On Safety

FDA’s second report to Congress on oversight of CBD market includes results from studies of whether products are mislabeled or adulterated, but also indicates throughout that more data are needed on safety of hemp-derived CBD ingredients used in myriad consumer health, cosmetic and food products already available.

US House Appropriators Keep A Bullseye On FDA’s CBD Regulation Development

Appropriations subcommittee notes the funding in summary of its draft budget bill. Language on FDA’s development of CBD regulatory framework will be included in panel’s report to be released 24 hours before full committee’s markup.

CV Sciences Eagerly Anticipating FDA Rulemaking On CBD In Dietary Supplements

Duffy MacKay, senior VP of scientific and regulatory affairs at CV Sciences, offers his predictions regarding the FDA’s likely course in regulating CBD’s use in dietary supplements – action that is sorely needed as the market continues to crowd with CBD products “with who-knows-what in them.”

Related Content

Topics

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel